Infant acute lymphoblastic leukemia: Lessons learned and future directions.

abstract：:Hodgkin lymphoma (HL) is a rare malignancy of the lymphatic system that is curable in at least 80 % of patients. Although patients usually present with painless lymphadenopathy, a variety of systemic and organ-specific syndromes may also exist in relation to HL. These syndromes may develop before, during, or after the...

journal_title：Current hematologic malignancy reports

authors： Barber NA,Bierman PJ

更新日期：2012-09-01 00:00:00

abstract：:Myeloproliferative neoplasms (MPNs) are stem cell-derived clonal myeloid malignancies characterized by a unique somatic mutational profile since three mutually exclusive mutations (JAK2V617F, MPL, and CALR) sustain the great majority of the cases. However, clinical observation that autoimmune diseases may predispose t...

journal_title：Current hematologic malignancy reports

authors： Barosi G

更新日期：2014-12-01 00:00:00

abstract：:High-dose chemotherapy with autologous stem cell transplantation (ASCT) has been shown to improve survival in patients with multiple myeloma in randomized trials and is the standard of care for eligible patients. Recent randomized trials suggest a survival benefit with tandem ASCT, notably for patients failing to achi...

journal_title：Current hematologic malignancy reports

authors： Kumar S

更新日期：2007-05-01 00:00:00

abstract：:The original version of this article unfortunately contained a mistake. The conflict of interest statement was incorrect. The corrected statement is given below. ...

journal_title：Current hematologic malignancy reports

authors： Zappasodi R,Wolchok JD,Merghoub T

更新日期：2019-02-01 00:00:00

abstract：PURPOSE OF REVIEW:This review discusses the current standard of care for incorporation of FLT3 TKIs and HCT into the treatment of FLT3-ITD AML. Additionally, this review provides an approach to the patient with relapsed/refractory disease. RECENT FINDINGS:Over the last decade, the routine use of HCT as consolidative t...

journal_title：Current hematologic malignancy reports

authors： Hunter BD,Chen YB

更新日期：2020-02-01 00:00:00

abstract：PURPOSE OF REVIEW:Over the past two decades, the introduction of tyrosine kinase inhibitors (TKIs) has transformed the treatment of chronic myeloid leukemia (CML). With four agents currently approved for frontline use in chronic-phase (CP) disease, it follows that treatment decision-making has been rendered more challe...

journal_title：Current hematologic malignancy reports

authors： Kennedy JA,Hobbs G

更新日期：2018-06-01 00:00:00

abstract：PURPOSE OF REVIEW:This article will review the use of anti-CD19 CAR-T therapy used in relapsed/refractory diffuse large B cell lymphoma. RECENT FINDINGS:The clinical outcomes, safety analysis, and other relevant considerations will be discussed with an emphasis on the most recently published data regarding the ZUMA-1,...

journal_title：Current hematologic malignancy reports

authors： Havard R,Stephens DM

更新日期：2018-12-01 00:00:00

abstract：:The clonal blood disorders polycythemia vera, essential thrombocythemia and primary myelofibrosis belong to the BCR-ABL1-negative myeloproliferative neoplasms and are specified by increased production of terminally differentiated myeloid cells. Clonal evolution, disease initiation and progression are influenced by gen...

journal_title：Current hematologic malignancy reports

authors： Them NC,Kralovics R

更新日期：2013-12-01 00:00:00

abstract：:The introduction of imatinib represented a breakthrough in the treatment of chronic myelogenous leukemia (CML). However, about 20% of patients treated in early chronic-phase CML are off therapy after 6 years because of resistance or intolerance, and most patients taking imatinib remain BCR-ABL-positive at the molecula...

journal_title：Current hematologic malignancy reports

authors： La Rosée P,Hochhaus A

更新日期：2008-04-01 00:00:00

abstract：PURPOSE OF REVIEW:To provide an update on the pathogenesis of enteropathy-associated T cell lymphoma (EATL) and its relationship with refractory celiac disease (RCD), in light of current knowledge of immune, genetic, and environmental factors that promote neoplastic transformation of intraepithelial lymphocytes (IELs)....

journal_title：Current hematologic malignancy reports

authors： Chander U,Leeman-Neill RJ,Bhagat G

更新日期：2018-08-01 00:00:00

abstract：PURPOSE OF REVIEW:Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare malignancy derived from plasmacyoid dendritic cells whose biology, clinical features, and treatment options are increasingly better understood. RECENT FINDINGS:TCF4 is a master regulator that drives donwstream transcriptional programs in ...

journal_title：Current hematologic malignancy reports

authors： Khoury JD

更新日期：2018-12-01 00:00:00

abstract：:Most non-Hodgkin lymphomas (NHL) are of B-cell origin; only about 10% are T-cell or NK-cell lymphomas. The clinical features of T/NK-cell lymphomas differ from those of B-cell lymphomas: advanced stage and extranodal disease are more common and the prognosis is worse. Several studies have confirmed that 2-[fluorine-18...

journal_title：Current hematologic malignancy reports

authors： Zinzani PL

更新日期：2011-12-01 00:00:00

abstract：PURPOSE OF REVIEW:To discuss the impact that next-generation sequencing has had on myeloproliferative neoplasm prognosis and treatment response. RECENT FINDINGS:Extended genetic testing has led to a more comprehensive understanding of the mutational landscape in the myeloproliferative neoplasms. More refined prognosti...

journal_title：Current hematologic malignancy reports

authors： Mina AA,Stein B

更新日期：2019-06-01 00:00:00

abstract：:The DNA hypomethylating agents (HMAs) azacitidine and decitabine are currently the most frequently administered disease-modifying therapies for patients with higher-risk myelodysplastic syndromes (MDS). However, azacitidine and decitabine are not curative, the median response duration is 11-15 months, and only 10-20 %...

journal_title：Current hematologic malignancy reports

authors： Roberts DA,Steensma DP

更新日期：2015-09-01 00:00:00

abstract：PURPOSE OF REVIEW:The use of circulating tumor DNA (ctDNA) for the purposes of diagnosis, prognosis, assessment of treatment response, and monitoring for relapse is a new and developing field in lymphoma. This review aims to summarize many of the most recent advances in ctDNA applications. RECENT FINDINGS:Recent studi...

journal_title：Current hematologic malignancy reports

authors： Darrah JM,Herrera AF

更新日期：2018-10-01 00:00:00

abstract：:Multiple myeloma (MM) is characterized by abnormal proliferation of plasma cells in the bone marrow leading to symptoms of anemia, renal failure, hypercalcemia, and bone lesions. Bone imaging is critical for the diagnosis, staging, assessment for the presence and extent of bone lesions, and initial treatment of MM. Sk...

journal_title：Current hematologic malignancy reports

authors： Raza S,Leng S,Lentzsch S

更新日期：2017-06-01 00:00:00

abstract：PURPOSE OF REVIEW:Social media has dramatically changed the access and exchange of information in healthcare and beyond. A variety of platforms and resources exist allowing blood and marrow transplant providers, researchers, and patients to interact. We review the adoption of social media by the transplantation communi...

journal_title：Current hematologic malignancy reports

authors： Patel SS,Majhail NS

更新日期：2018-12-01 00:00:00

abstract：:Chronic myeloid leukemia (CML) arises as a consequence of a chromosomal translocation giving rise to the Philadelphia chromosome and Bcr-Abl oncogene. CML is a clonal disease of stem cell origin and an excellent example of a malignancy in which tumor-initiating cells may hold the key to disease eradication. The known ...

journal_title：Current hematologic malignancy reports

authors： Helgason GV,Young GA,Holyoake TL

更新日期：2010-04-01 00:00:00

abstract：PURPOSE OF REVIEW:CMV DNA polymerase inhibitors such as ganciclovir and foscarnet have dramatically reduced the burden of CMV infection in the HCT recipient. However, their use is often limited by toxicities and resistance. Agents with novel mechanisms and favorable toxicity profiles are critically needed. We review re...

journal_title：Current hematologic malignancy reports

authors： Hakki M

更新日期：2020-04-01 00:00:00

abstract：:Allogeneic haematopoietic cell transplantation continues to be an important curative therapy for acute lymphoblastic leukaemia (ALL). Traditionally accepted indications for allografting adult ALL patients need reevaluation in light of outcomes with paediatric-like intensive regimens. Minimal residual disease status an...

journal_title：Current hematologic malignancy reports

authors： Dhawan R,Marks DI

更新日期：2017-04-01 00:00:00

abstract：:In recent years, the treatment of multiple myeloma has undergone significant changes. The availability of novel agents bortezomib, thalidomide and lenalidomide considerably improved the outcome of patients. The advantages related to the use of novel agents have been shown in various studies in patients eligible and in...

journal_title：Current hematologic malignancy reports

authors： Guglielmelli T,Palumbo A

更新日期：2013-12-01 00:00:00

abstract：:Mycosis fungoides (MF) and its leukemic variant, Sézary syndrome (SS), are malignancies of skin-homing T cells that comprise the majority of cutaneous T cell lymphomas (CTCL). Treatment of CTCL is limited and can be approached by skin-directed therapy or systemic therapy. Recent investigations into the pathogenesis of...

journal_title：Current hematologic malignancy reports

authors： Chung CG,Poligone B

更新日期：2015-12-01 00:00:00

abstract：:Among the few drugs that have shown a benefit for patients with acute myeloid leukemia (AML) in randomized clinical trials over the last several decades is the CD33 antibody-drug conjugate, gemtuzumab ozogamicin (GO). Undoubtedly, this experience has highlighted the value of antigen-specific immunotherapy in AML. A wi...

journal_title：Current hematologic malignancy reports

authors： Buckley SA,Walter RB

更新日期：2015-06-01 00:00:00

abstract：PURPOSE OF REVIEW:There are limited treatment options for relapsed/refractory classical Hodgkin lymphoma (cHL) patients who progress on brentuximab vedotin and programmed death-1 inhibitors. Camidanlumab Tesirine (Cami) is a new agent that has shown activity in multiply relapsed/refractory cHL patients. In this review,...

journal_title：Current hematologic malignancy reports

authors： Epperla N,Hamadani M

更新日期：2021-01-25 00:00:00

abstract：:Acute myeloid leukemia (AML) is a very heterogeneous disease. Prognosis is related not only to intrinsic characteristics such as cytogenetics and molecular markers, but also the patient's ability to tolerate therapy, and treatment response. Allogeneic stem cell transplantation (allo-HCT) has been traditionally indicat...

journal_title：Current hematologic malignancy reports

authors： Lekakis LJ,Cooper BW,de Lima MG

更新日期：2014-06-01 00:00:00

abstract：:A high risk of arterial and venous thrombosis is the hallmark of chronic myeloproliferative neoplasms (MPNs), particularly polycythemia vera (PV) and essential thrombocythemia (ET). Clinical aspects, pathogenesis and management of thrombosis in MPN resemble those of other paradigmatic vascular diseases. The occurrence...

journal_title：Current hematologic malignancy reports

authors： Finazzi G,De Stefano V,Barbui T

更新日期：2013-12-01 00:00:00

abstract：:Advances in drug discovery have led to the use of effective targeted agents in the treatment of hematologic malignancies. Drugs such as proteasome inhibitors in multiple myeloma and tyrosine kinase inhibitors in chronic myeloid leukemia and non-Hodgkin lymphoma have changed the face of treatment of hematologic maligna...

journal_title：Current hematologic malignancy reports

authors： Sethi TK,Basdag B,Bhatia N,Moslehi J,Reddy NM

更新日期：2017-06-01 00:00:00

abstract：:The prognosis value of interim positron emission tomography (PET) remains controversial in diffuse large B-cell lymphoma (DLBCL) patients because of the absence of consensus on criteria able to early identify good and bad responders to treatment. Visual interpretation using the International Harmonization Project (IHP...

journal_title：Current hematologic malignancy reports

authors： Casasnovas RO,Meignan M,Berriolo-Riedinger A,Itti E,Huglo D,Haioun C,Morschhauser F

更新日期：2012-09-01 00:00:00

abstract：PURPOSE OF REVIEW:Determine if therapy of chronic myeloid leukaemia (CML) is a model for treating other cancers. RECENT FINDINGS:CML has a relatively homogeneous phenotype and genotype and is caused by one mutation, BCRABL1, in every instance. In contrast, most other leukaemias, haematologic cancers and solid cancer h...

journal_title：Current hematologic malignancy reports

authors： Gale RP,Apperley J

更新日期：2019-12-01 00:00:00

abstract：:BCR-ABL-negative myeloproliferative neoplasms include primary myelofibrosis, polycythemia vera, and essential thrombocythemia. Clonal stem cell proliferation and dysregulated JAK/STAT molecular pathways characterize these hematologic malignancies. Symptoms experienced by patients are heterogeneous including excessive ...

journal_title：Current hematologic malignancy reports

authors： Scherber RM,Geyer HL,Mesa RA

更新日期：2014-12-01 00:00:00